Orthocell’s ‘Cell Factory’ validated for bone regeneration

Company News

Regenerative medicine company Orthocell (ASX:OCC) has announced the presentation of its successful ‘cell factory’ data at the European Bone and Joint Infection Society in Portugal.

The data was generated as a result successful collaboration with institutes in Sweden, Australia, Denmark, India and UK.

Orthocell said the data supports the intellectual property around the generation of ‘tissue specific’ growth factors for the regeneration of cartilage and bone and follows on from the Cell Factory work for the cartilage injuries that it announced in May.

“Unhealed fractures, particularly those involving infections is one of the most difficult orthopaedic conditions to treat and this work holds great promise for an effective solution” said Orthocell CEO, Paul Anderson.

“This has the potential to be a clinically effective and cost effective approach for the regeneration of chronic bone defects,” he said.